SOCIUM Inc

SOCIUM is an AI-powered drug discovery and development company focused on first-in-class small molecules.

SOCIUM Inc operates in health based in Tokyo, Japan, founded in 2017.

Profile

SOCIUM is an AI-powered drug discovery and development company focused on first-in-class small molecules. The company currently has a development portfolio of over 23 diseases, including oncology and rare diseases. The company replaces multiple steps in the traditional drug discovery process with an in-silico system using our cutting edge algorithm, established a system to identify the drug discovery target in a few months. By taking a systems biology approach using our Augmented intelligence and Machine Learning – instead of hypothesizing the mechanism of a disease and focusing on only a few related compounds, we profile the entire disease by analyzing various OMICS data.

Within the health space, the company focuses on its core offering rather than a broad product line.

The business is associated with Tokyo, Japan.

It is recorded at the Seed stage.

The company reports a headcount in the c_00011_00050 range.

Public records show total funding of about $260M.

Website: socium.co.jp